-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

David Z. I. Cherney, MD, PhD

Articles by David Z. I. Cherney, MD, PhD

Validation of the FINE-CKD Model for Future Health Technology Assessments for Finerenone in Patients With Chronic Kidney Disease And Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Aleksandra Drzewiecka, MSc,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Monika Palarczyk, MSc,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

August 16th 2022

FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

December 8th 2021

eAppendix: FINE-CKD Model to Evaluate Economic Value of Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes

ByMichał Pochopień, MSc,David Z. I. Cherney, MD, PhD,Kerstin Folkerts, MSc,Pierre Levy, PhD,Aurélie Millier, PhD,Stephen Morris, PhD,Prabir Roy-Chaudhury, MD, PhD,Sean D. Sullivan, PhD,Paul Mernagh, MCom

December 8th 2021

Latest Updated Articles

Trending on AJMC

Patient Portal Messages Outpace Office Visits

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

Social Factors May Match, Outpace Genetic Risk in Disease Prediction

Long-Term, Consistent Resistance Training Linked to Substantially Lower Type 2 Diabetes Risk